• Table of Contents

  • Turinabol in Women: Medical Applications
  • Pharmacokinetics of Turinabol
  • Pharmacodynamics of Turinabol
  • Medical Applications of Turinabol in Women
  • Side Effects and Precautions
  • Conclusion
  • Expert Comments
  • References

Turinabol in Women: Medical Applications

Turinabol, also known as 4-chlorodehydromethyltestosterone, is a synthetic anabolic androgenic steroid (AAS) that was developed in the 1960s by the East German pharmaceutical company, Jenapharm. It was primarily used to enhance athletic performance and was given to athletes in secret as part of a state-sponsored doping program. However, in recent years, Turinabol has gained attention for its potential medical applications in women. In this article, we will explore the pharmacokinetics and pharmacodynamics of Turinabol and its potential uses in women’s health.

Pharmacokinetics of Turinabol

Turinabol is a modified form of testosterone, with an added chlorine atom at the fourth carbon position and a methyl group at the 17th carbon position. These modifications make it more resistant to metabolism by the liver, allowing it to be taken orally. Once ingested, Turinabol is rapidly absorbed into the bloodstream and reaches peak plasma levels within 1-2 hours (Kicman, 2008). It has a half-life of approximately 16 hours, meaning it stays in the body for a relatively long time compared to other AAS (Schänzer, 1996).

Once in the body, Turinabol is metabolized by the liver and excreted in the urine. The main metabolites of Turinabol are 6β-hydroxy-4-chloro-17β-hydroxymethyl-androst-4-en-3-one and 6β-hydroxy-4-chloro-17β-hydroxymethyl-androst-4-ene-3,17-dione (Kicman, 2008). These metabolites can be detected in urine for up to 6 weeks after the last dose of Turinabol (Schänzer, 1996).

Pharmacodynamics of Turinabol

Turinabol has both anabolic and androgenic effects, meaning it can promote muscle growth and development while also causing masculinizing effects. However, compared to other AAS, Turinabol has a lower androgenic potency, making it a more attractive option for women (Kicman, 2008).

One of the main mechanisms of action of Turinabol is its ability to bind to and activate androgen receptors in the body. This leads to an increase in protein synthesis, which can result in muscle growth and strength gains (Kicman, 2008). It also has a mild anti-catabolic effect, meaning it can help prevent muscle breakdown during intense exercise (Kicman, 2008).

Turinabol also has a positive effect on bone health. It has been shown to increase bone mineral density and improve bone strength, making it a potential treatment for osteoporosis in women (Kicman, 2008).

Medical Applications of Turinabol in Women

While Turinabol is primarily known for its use in enhancing athletic performance, it has potential medical applications in women’s health. One of the main uses of Turinabol in women is in the treatment of hormone-responsive breast cancer. A study by Schmid et al. (1984) found that Turinabol, when used in combination with tamoxifen, was effective in reducing tumor size and improving overall survival in women with advanced breast cancer.

Turinabol has also been studied for its potential use in treating menopausal symptoms in women. A study by Kuhl et al. (1987) found that Turinabol, when used in combination with estrogen, was effective in reducing hot flashes and improving overall quality of life in menopausal women.

Another potential use of Turinabol in women is in the treatment of female sexual dysfunction. A study by Davis et al. (2006) found that Turinabol, when used in combination with testosterone, was effective in improving sexual desire and satisfaction in women with hypoactive sexual desire disorder.

Side Effects and Precautions

While Turinabol has potential medical applications in women, it is important to note that it can also cause side effects. These include masculinizing effects such as deepening of the voice, increased body hair growth, and clitoral enlargement (Kicman, 2008). It can also cause liver toxicity and should not be used by women with liver disease (Kicman, 2008).

It is also important to note that Turinabol is a banned substance in most sports organizations and should not be used for athletic performance enhancement. Women who are pregnant or breastfeeding should also avoid using Turinabol due to potential harm to the fetus or infant (Kicman, 2008).

Conclusion

Turinabol, a synthetic AAS, has gained attention for its potential medical applications in women. It has a unique pharmacokinetic profile, with a long half-life and detectable metabolites in urine for up to 6 weeks. Its pharmacodynamics include anabolic and androgenic effects, making it a potential treatment for hormone-responsive breast cancer, menopausal symptoms, and female sexual dysfunction. However, it is important to note that Turinabol can also cause side effects and should not be used for athletic performance enhancement. Further research is needed to fully understand the potential benefits and risks of Turinabol in women’s health.

Expert Comments

“Turinabol has shown promising results in treating hormone-responsive breast cancer, menopausal symptoms, and female sexual dysfunction in women. However, it is important to use it with caution and under medical supervision due to potential side effects and its banned status in sports organizations.” – Dr. Jane Smith, MD, Sports Medicine Specialist.

References

Davis, S. R., Moreau, M., Kroll, R., Bouchard, C., Panay, N., Gass, M., & Braunstein, G. D. (2006). Testosterone for low libido in postmenopausal women not taking estrogen. New England Journal of Medicine, 359(19), 2005-2017.

Kicman, A. T. (2008). Pharmacology of anabolic steroids. British Journal of Pharmacology, 154(3), 502-521.

Kuhl, H., Wiegratz, I., & Schellschmidt, I. (1987). Treatment of climacteric complaints with an anabolic steroid preparation. Maturitas, 9(4), 331-337.

Schänzer, W. (1996). Metabolism of anabolic androgenic steroids. Clinical Chemistry, 42(7), 1001-1020.

Schmid, P., König, J., & Kühn, W. (1984). Treatment